CRISPR Therapeutics AG
CRSP
주식 순위
#3544
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
주가
$50.26
시가총액
$4.86B
변동 (1일)
0.43%
변동 (1년)
-32.06%
국가
CH
거래 CRISPR Therapeutics AG (CRSP)
카테고리
Healthcare
CRISPR Therapeutics AG (CRSP)의 주식 분할 이력
CRISPR Therapeutics AG 주식 (심볼: CRSP)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Oct 20, 2026에 발생했습니다.
Oct 20, 2026 이전에 매수한 CRSP 주식 1주는 현재 0주의 CRSP 주식에 해당합니다.
가장 최근의 분할은 Oct 20, 2026에 발생했습니다.
Oct 20, 2026 이전에 매수한 CRSP 주식 1주는 현재 0주의 CRSP 주식에 해당합니다.
주식 분할 목록
| 연도 | 주식 분할 | 배수 | 누적 배수 |
|---|---|---|---|
| 제공된 날짜에 대한 데이터가 충분하지 않습니다. | |||
유사 기업 또는 경쟁사의 주식 분할
| 회사 | 주식 분할 횟수 | 누적 배수 | 국가 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
